Tardive Dyskinesia

New England CEPAC

Tardive dyskinesia is a serious and disabling movement disorder that affects individuals treated with antipsychotic agents for a variety of mental health conditions. Though prevention and treatment primarily focus on stopping or changing the offending antipsychotic agent, for some individuals there are no other effective treatment options, and symptoms can persist after discontinuing or changing antipsychotic therapy.

Interventions of Interest:

  • Valbenazine (IngrezzaTM, Neurocrine Biosciences, Inc)
  • Deutetrabenazine (AustedoTM, Teva)
  • Tetrabenazine (Xenazine®)

Date of Review: December 2017

Associated Meetings

The New England CEPAC will convene to review ICER's evidence report assessing the clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder related to prolonged use of antipsychotic medications.


Key Dates

Associated Materials

04/21/2017 – 05/12/2017

05/08/2017

05/08/2017

05/08/2017 – 05/26/2017

06/09/2017

07/12/2017

07/12/2017

10/02/2017
Draft Evidence Report

10/02/2017
Draft Voting Questions

10/02/2017 – 10/30/2017
Public Comments

11/21/2017
Evidence Report

11/21/2017
Revised Voting Questions

12/05/2017
Meeting Agenda

12/21/2017
Final Evidence Report and Meeting Summary